These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33705807)

  • 1. Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review.
    Tan Y; Fukutomi A; Sun MT; Durkin S; Gilhotra J; Chan WO
    Surv Ophthalmol; 2021; 66(6):926-932. PubMed ID: 33705807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of intravitreal anti-VEGF therapy on intraretinal microvascular abnormalities in proliferative diabetic retinopathy.
    De Geronimo D; Parravano M; Sacconi R; Fragiotta S; Giannini D; Costanzo E; Varano M; Querques G
    Acta Diabetol; 2024 Apr; 61(4):525-528. PubMed ID: 38302784
    [No Abstract]   [Full Text] [Related]  

  • 3. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy.
    Bolinger MT; Antonetti DA
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy.
    Shye M; Hanna RM; Patel SS; Tram-Tran N; Hou J; Mccannel C; Khalid M; Hanna M; Abdelnour L; Kurtz I
    Clin Kidney J; 2020 Dec; 13(6):969-980. PubMed ID: 33391740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress of Nanotechnology in Diabetic Retinopathy Treatment.
    Liu Y; Wu N
    Int J Nanomedicine; 2021; 16():1391-1403. PubMed ID: 33658779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vision loss, tractional retinal detachment, and profound anemia due to rectal carcinoma.
    Yamamoto A; Nishimura Y; Obika M; Morizane Y; Otsuka F
    Clin Case Rep; 2020 Jul; 8(7):1304-1305. PubMed ID: 32695381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs.
    Kim HM; Woo SJ
    Curr Ther Res Clin Exp; 2024; 100():100742. PubMed ID: 38617894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NATURAL HISTORY AND PREDICTORS OF VISION LOSS IN EYES WITH DIABETIC MACULAR EDEMA AND GOOD INITIAL VISUAL ACUITY.
    Lent-Schochet D; Lo T; Luu KY; Tran S; Wilson MD; Moshiri A; Park SS; Yiu G
    Retina; 2021 Oct; 41(10):2132-2139. PubMed ID: 33734192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
    Mitchell P; Holz FG; Hykin P; Midena E; Souied E; Allmeier H; Lambrou G; Schmelter T; Wolf S;
    Retina; 2021 Sep; 41(9):1911-1920. PubMed ID: 33782365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry.
    Hunt AR; Nguyen V; Creuzot-Garcher CP; Alforja S; Gabrielle PH; Zarranz-Ventura J; Guillemin M; Fraser-Bell S; Casaroli Marano RP; Arnold J; McAllister IL; O'Toole L; Gillies MC; Barthelmes D; Mehta H
    Br J Ophthalmol; 2022 Aug; 106(8):1178-1184. PubMed ID: 33712484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of Managing Diabetic Macular Edema With Good Visual Acuity With Aflibercept, Laser, or Observation: DRCR Retina Network Protocol V.
    Hutton DW; Glassman AR; Stein JD; Bressler NM; Sun JK;
    Am J Ophthalmol; 2021 Oct; 230():297-302. PubMed ID: 33713680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective study of aflibercept in combination therapy for high-risk proliferative diabetic retinopathy and diabetic maculopathy.
    Tao Y; Jiang P; Zhao Y; Song L; Ma Y; Li Y; Wang H
    Int Ophthalmol; 2021 Jun; 41(6):2157-2165. PubMed ID: 33772699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature.
    Berrocal MH; Acaba-Berrocal L
    Curr Opin Ophthalmol; 2021 May; 32(3):203-208. PubMed ID: 33770016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Ranibizumab Versus Aflibercept for Diabetic Macular Edema in Vitrectomized Eyes: 12 Month Results.
    Türkseven Kumral E; Erçalık NY
    Semin Ophthalmol; 2021 Nov; 36(8):723-727. PubMed ID: 33760698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intravitreal injections of Ranibizumab and Aflibercept in neovascular age related macular degeneration.
    Sizmaz S; Esen E; Isik-Ericek P; Demircan N
    Clin Exp Optom; 2022 Jan; 105(1):55-60. PubMed ID: 33719869
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-related adverse effects of antivascular endothelial growth factor agents.
    Iyer PG; Albini TA
    Curr Opin Ophthalmol; 2021 May; 32(3):191-197. PubMed ID: 33770015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitreomacular interface after anti-VEGF injections in diabetic macular edema.
    Veloso CE; Brocchi DN; Singh RP; Nehemy MB
    Int J Retina Vitreous; 2021 Mar; 7(1):23. PubMed ID: 33741068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optical Coherence Tomography Biomarkers in Bilateral Diabetic Macular Edema Patients with Asymmetric anti-VEGF Response.
    Koc F; Güven YZ; Egrilmez D; Aydın E
    Semin Ophthalmol; 2021 Aug; 36(5-6):444-451. PubMed ID: 33780313
    [No Abstract]   [Full Text] [Related]  

  • 20. Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen.
    Aslanis S; Amrén U; Lindberg C; Epstein D
    Ophthalmol Retina; 2022 Jan; 6(1):15-20. PubMed ID: 33775926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.